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Worldwide HIV-1 vaccine efforts are guided by the principle that
HIV-specific T cell responses may provide protection from infection
or delay overt disease. However, no clear correlates of T cell-
mediated immune protection have been identified. Here, we ex-
amine in a HLA-B27 HIV seronegative vaccinee persistent HIV-
specific vaccine-induced anti-Gag CD4 and CD8 T cell responses.
Although these responses exhibited those characteristics (multi-
functionality, appropriate memory phenotype, and targeting of
epitopes associated with long-term nonprogression) predicted to
correlate with protection from infection, the subject became HIV
infected. After HIV infection, the vaccine-induced CD8 T cells
expanded, but both CD4 and CD8 T cell responses acquired the
functional and phenotypic patterns characteristic of chronic HIV
infection. The virus quickly escaped the vaccine-induced T cell
response, and the subject progressed more rapidly than expected
for someone expressing the HLA-B27 allele. These data suggest
that control of HIV by vaccine-elicited HIV-specific T cell responses
may be difficult, even when the T cell response has those charac-
teristics predicted to provide optimal protection.
acute infection  correlate of protection  multiparameter flow cytometry
Several phase I and II clinical trials investigating HIV vaccinecandidates conducted worldwide are based on the prevailing
notion that both HIV-specific CD4 and CD8 T cell responses
may be required to confer protection from disease progression (1).
However, the correlates of immune protection remain unclear and
controversial.
The properties likely to be required in a protective HIV-specific
T cell response include high frequency, polyclonal, multifunctional
CD4 and CD8 T cells of broad specificity, capable of prolifer-
ation and differentiation from central memory to effector memory
phenotype that ideally recognize conserved HIV epitopes (1).
Further, T cells have amyriad of functions, yet those that are critical
for controlling HIV replication, preventing disease progression, or
providing vaccine-induced protection are unknown. We know that
CD8 T cells place substantial pressure on HIV with repercussions
for virus fitness (2), and that CD4 T cell responses may be pivotal
for the generation of long-lasting, fully functional CD8 T cell
responses (3, 4). Although selective T cell memory phenotypes are
likely to play a decisive role in long-term protection from challenge
against chronic viral infections in animals (5), these features are still
unresolved for chronic virus infection in humans.
Here, we present the sentinel analysis of vaccine-induced mul-
tifunctional anti-HIV Gag-specific CD4 and CD8 T cell re-
sponses in a HLA-B*2705 HIV-vaccine recipient, their changes
after infection, and how they compare with those detectable in two
nonvaccinated HLA-B*2705 chronically HIV-infected individu-
als. The results underscore our lack of understanding regarding the
immune correlates of protection both in HIV disease and vaccine
models.
Materials and Methods
Subjects and Study Protocols. Peripheral blood mononuclear cells
(PBMC) were obtained from a HLA-B*2705 positive volunteer
(202-T07) enrolled in the National Institutes of Health-sponsored
AIDS Vaccine Evaluation Group protocol 202 that evaluated the
immunogenicity of a recombinant canarypox vector vCP205 (ex-
pressing gp120MN, the transmembrane portion of gp41LAI 688–712,
GagLAI, and proteaseLAI; Pasteur-Merieux Connaught Laborato-
ries, North York, ON, Canada) (6). This individual received four
vector injections over a 6-month period. For comparative purposes,
we studied anti-Gag T cell responses in two chronically HIV-1-
infected HLA-B*2705-positive subjects who were enrolled at the
Adult HIV Clinic of the University of Alabama at Birmingham.
PBMC samples were obtained from all of the subjects under signed
informed consent approved by all of the institutions. For subject
202-T07, postinfection time points are referred to as ‘‘acute’’ and
‘‘chronic,’’ where acute is the initial clinic visit and chronic is 28
months after the acute time point. The MHC class I haplotypes of
the subjects in this study are as follows: 202-T07: HLA-A2, B2744,
and Cw25; 2714A: HLA-A230, B2742, and Cw217; 3963I:
HLA-A12, B827, and Cw46.
Peptides. The 15- and 20-mer overlapping peptides of the HIV-
1HXB2 subtypeB gene products were provided through theNational
Institutes of Health AIDS Research and Reference Reagent Pro-
grams. The 9-mer overlapping peptides and optimal epitopic pep-
tides were purchased at90%HPLC purity from SynPep, Dublin,
CA. For the purpose of epitope mapping, a peptide matrix analysis
was used as described in ref. 7.
Antibodies Source. The source for each antibody used in this study
is reported in Supporting Text, which is published as supporting
information on the PNAS web site.
This paper was submitted directly (Track II) to the PNAS office.
Freely available online through the PNAS open access option.
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CTL Studies. PBMC were separated from 50 ml of acid citrate
dextrose anti-coagulated blood, and CD8 CTL responses were
evaluated by using autologous 51Cr-labeled target cells pulsed with
defined peptides, infected with the appropriate recombinant vac-
cinia constructs, orwith autologous virus isolates as reported in refs.
7 and 8. To generate KK10-specific CD8 T cell lines, PBMC were
stimulated and cultured according to the method in ref. 7.
IFN- ELISpot Assay. A modified ELISpot assay was used to detect
peptide-specific release of IFN- by cryopreserved PBMC as
described in ref. 7.
T Cell Receptor B (TCRB) Gene Expression Analysis. B27KK10
tetramerCD8 T cells were sorted to99% purity and the CDR3
region of the TCRB gene was sequenced according to procedures
in ref. 9 (see Supporting Text for details).
Intracellular Cytokine Staining and Degranulation Assay.PBMCwere
thawed and rested overnight at 37°C, in 5% CO2 atmosphere, in
RPMImedium 1640 containing 10% FCS (R10). The next day, the
cells were adjusted to 1 106 per ml. In four-color flow, cells were
stimulated and stained according tomethods in ref. 7. In nine-color
flow, cells were stimulated and stained as described in ref. 10. We
used the following mAbs: CD107a-Alexa 680, CD4-Cascade
Blue, CD14CD19-Cy5PE, CD3-Cy7APC, CD8-TRPE,
-IFN--FITC, TNF -Cy7PE, and IL-2-APC. In all experi-
ments, a negative control (CD2849d), and a positive control
(staphylococcal enterotoxin B, 10 gml, Sigma-Aldrich) were
included.
The results are reported as pie charts that depict the contribution
of various responding T cell populations (background adjusted) to
the total peptide-specific response (see Figs. 2, 4, and 5). Each
portion of the pie chart represents a single population of CD8 or
CD4 T cells expressing the marker depicted by the concentric
colored arcs (red, CD107a; blue, IFN-; green, IL-2; orange,
TNF-) surrounding the pie chart. The color table used to generate
the pie charts within all figures is matched, allowing direct com-
parison of the relative size of each responding population between
each pie chart.
Memory Phenotyping. PBMC were rested overnight and stained
with phycoerythrin (PE)-labeled B27KK10 tetramers for 15 min,
followed by mAbs CD45RO-TRPE, CD28-APC, and CD57-
Cascade Blue in the following combinations: 1: CD3-Cy7APC,
CD8-Cy5.5APC, CD27-Cy5PE, CD45RA-Cy5.5PE, CCR7-
Cy7PE, andCD1419-FITC; and 2:CD3-Cy5PE,CD8-Cy7PE,
CD27-FITC, CCR7-Alexa 680. Although only the particular
combinations of mAbs that gave the best discrimination of the
various memory phenotypes of the total CD8 T cells and the
tetramer population were selected for presentation, all stains
Fig. 1. Initial characterization of the vaccine-induced CD8 T cell response. (a) IFN- ELISpot was performed to map the vaccine-induced response in HIV Gag.
Either Gag Pool or individual peptides overlapping by a single amino acid spanning the region of HIV Gag p24261–280 were used on PBMC obtained at visit 8. (b)
The KK10-specific CD8 T cells could be detected at visits 8 (data not shown) and 13, but not before the first immunization (visit 2), by using direct staining with
B27KK10 tetramer. The number shown on the plot represents the percentage of B27KK10 CD8 T cells. (c) Memory phenotype of the KK10-specific CD8 T
cells, shown in red, are overlaid onto the total CD8 T cell memory phenotype (grayblue density plot). (d) The KK10-specific CD8 T cells produce IFN- after
peptide stimulation. The values on the plots represent the percentage frequency of IFN--producing CD8 T cells.









could be used to confirm the memory phenotype of the cells being
examined. For Figs. 1c, 3c, and 5c, the panels represent, from left
to right, the following combinations of markers: CD27CD45RO,
CCR7CD45RO, CD27CD28, and CD57CD28.
Flow Cytometer. Four-color analysis was performed on a FACS-
Calibur. Nine- and 10-color analysis was performed on either a
FACS Digital Vantage (Becton Dickinson) equipped for 12-color
analysis or an LSR II (Becton Dickinson) equipped for 18-color
analysis. Between 100,000 and 500,000 events were collected for
each sample. Data were analyzed by using FLOWJO software (Tree
Star, San Carlos, CA).
Viral Sequencing. Viral RNAs were isolated from 280-l patient
plasma with the Qiagen (Valencia, CA) viral mini kit. We se-
quenced plasma virus from an acute visit and 12, 24, and 32months
(chronic) postdiagnosis samples for patient 202-T07. One sample
obtained at time of study from 3963I and 2714A subjects was also
analyzed. The first strand of DNA was synthesized by using either
random hexamer primers or a gene specific primer cgagA 5-
TGATAAAACCTCCAATTCCCCCTAT-3 according to manu-
facturer’s protocol. Two rounds of PCR were carried out to obtain
sufficient quantities of amplification products for further subclon-
ing (PBS1A 5-TTTGCCTGTACTGGGTCTCTCTGGTT-3 and
cgagA in the first round; PBS1C 5-GCTTAAGCCTCAATA-
AAGCTTGCCTT-3 and cgagB 5-AATACTGTATCATCT-
GCTCCTGTATC-3 in the second round). About 20 clones from
each sample were sequenced on a PRISM 3100 Genetic Analyzer
(Applied Biosystems).
Supporting Information. For further information, see Figs. 6–9,
which are published as supporting information on the PNAS web
site.
Results
Study Participant Clinical Course.HIV-negative subject 202-T07 was
immunized with a recombinant canarypox vector vCP205. His final
vaccination occurred 168 days postfirst immunization (DPFI), and
he completed his final study visit on day 364 (visit 13). Eight
hundred DPFI (acute visit), the subject returned to the clinic
complaining of flu-like symptoms, and he admitted having unpro-
tected anal intercourse with an undisclosed HIV-infected homo-
sexual partner. Testing revealed a positive HIV ELISA antibody
test, an indeterminate Western blot, and a plasma viral load of
234,695 copies per ml indicative of recent HIV infection. He began
taking antiretroviral therapy that was discontinued on 1,240 DPFI
after he became only partially compliant. Although he remained
free of symptoms attributable to HIV off therapy, his CD4 count
continued to decline and viral replication was not effectively
controlled (Supporting Text and Fig. 6 include detailed clinical
course).
Characterization of vCP205-Induced Immune Responses. No Env-
specific antibody responses were detectable during the vaccine trial
(6). Two weeks after the last immunization (visit 8), cytotoxic T cell
activity against HIV Gag was detected by 51Cr release assay after
antigen-specific in vitro expansion (28% specific lysis; data not
shown). This response was mapped by IFN- ELISpot to the HLA
B*2705-restricted epitope Gag263–272, KRWIILGLNK (KK10; Fig.
1a). The KK10 response was detectable by using HLA-B27 KK10
(B27KK10) tetramers (Fig. 1b) at both visits 8 (data not shown)
and 13 but not before the first vaccination (visit 2). Phenotypically,
the B27KK10 tetramer CD8 T cells comprised central and
effectoreffector memory cells defined as CD27CD28
CCR7CD45ROCD57 and CD27CD28CCR7CD45RO
CD57, respectively, six months after the final vaccination (visit 13)
(Fig. 1c). The KK10-specific CD8 T cells were functional as
determined by intracellular cytokine staining for IFN- (Fig. 1d), at
both visits 8 and 13.
A more detailed analysis of the KK10-specific CD8 T cells
revealed a heterogenous functional profile (Fig. 2a; each sector of
the pie chart represents a subset expressing the marker depicted by
the concentric colored arcs). The total response to this epitope was
0.1% of all CD8 T cells; the dominant effector function was
TNF-production (75%of responding cells). About two-thirds of
responding CD8 T cells degranulated (CD107) (10). IL-2 was
produced by 10% of responding cells. IFN- production only
accounted for 50% of the total response. Therefore, we reexam-
ined the T cell response to full-length Gag by using overlapping
peptides with multiparameter flow cytometric analysis, and found
a much higher frequency of CD8 T cell response (0.7%), domi-
nated by cells that only degranulated (Fig. 2b). Additionally, we
noted an IL-2-producing population that constituted 25% of the
Gag response. The proportion of IFN--producing CD8 T cells
responding to the overlapping Gag peptides (0.05%) was equiv-
alent to the proportion of KK10-specific CD8 T cells. We also
observed a substantial CD4T cell response toGag (0.3%, Fig. 2c),
dominated by cells that produced IL-2 alone. Only a small number
of IL-2CD4T cells produced IFN- (0.02%).NoT cell responses
to HIV Env or Nef (encoded and not contained in the vaccine
vector, respectively) were detected. Because insufficient PBMC
samples remained to map the epitopes recognized by both the
Gag-specific CD4 and CD8 T cell response, it can be assumed
that subject 202-T07 recognized at least one CD4 epitope and two
CD8 epitopes (based on the larger response frequency) after the
final immunization dose.
Recall of Vaccine-Induced KK10-Specific CD8 T Cell Response After
Infection. After infection, the B27KK10 tetramerCD8 T cell
population had expanded from 0.05% (visit 13; 364 DPFI) to 9.8%
of total CD8 T cells (acute visit, 800 DPFI), but decreased to
2.96% at 1,700 DPFI (chronic visit) (Fig. 3a). The sequence of the
TCRB CDR3 region of the B27KK10 tetramerCD8 T cells
from T cell lines obtained from visit 13 and cells isolated directly ex
vivo from the acute and chronic visits indicate that the dominant
vaccine-induced clonotype that expanded in vitro was also the
Fig. 2. Fine characterization of vaccine-induced T lymphocyte functional
responses by using nine-color flow cytometry. The two left dot plots of each
row represent theunstimulated control, and the two right dot plots showcells
stimulated with KK10 peptide (a) or CD8 (b) or CD4 (c) overlapping Gag
peptides. The staining combination for each column of dot plots is shown at
the bottom of the figure. The pie charts (see Materials and Methods) depict
the contribution of various responding CD8 (a and b) or CD4 (c) T cell
populations (background adjusted).
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dominant clonotype observed during acute infection (Fig. 3b). Two
subdominant vaccine-induced clonotypeswere present during acute
infection, one of which had become substantially more prevalent.
Only two vaccine-induced clonotypes were maintained through to
chronic infection, at which time they were both subdominant. The
other clonotypes present at the chronic visit appear to have arisen
de novo after infection. None of the clonotypes observed in 202-T07
were similar to theKK10-specific CD8T cell clonotypes identified
in two HIV-infected subjects with HLA-B27-restricted KK10-
specific CD8 T cell responses (Fig. 3b).
After infection, de novo HIV-specific CD8 T cell responses
were detected against various viral epitopes in Gag, Pol, Env, Nef,
Vif, andVpr (Fig. 9), but theKK10-specific responsewas dominant.
One KK10-specific CD8 T cell line was expanded in vitro from
PBMC isolated at visit 13, and two were obtained from PBMC
isolated at the acute visit. These cell lines were all composed
primarily of the dominant vaccine-induced clonotype and lysed
autologous CD4 lymphoblastoid cell targets either coated with
KK10 peptide or infected with the autologous virus isolated from
the acute visit (data not shown). These findings indicate that the
dominant vaccine-induced clonotype maintained proliferative ca-
pacity and cytotoxic ability against autologous viruses after infec-
tion. None of these CD8 T cell lines exhibited noncytolytic
suppression of viral replication by using methods described in ref.
11 (Fig. 7).
After infection, the B27KK10 tetramerCD8 cells in subject
202-T07 rapidly switched to a predominantly effector
(CD27CD28CCR7CD45ROCD57)effector memory
(CD27CD28CCR7CD45ROCD57) phenotype (Fig. 3c). A
small proportion of the KK10-specific cells retained a central
memory (CD27CD28CCR7CD45ROCD57) phenotype.
Similar phenotypic characteristics were observed in the KK10-
specific CD8 T cells in the control subjects (see Fig. 5c).
Shift in T Cell Functional Profile After Infection. Before infection, the
vCP205-induced KK10-specific CD8 T cells in subject 202-T07
produced predominantly TNF- upon stimulation. After infection,
the KK10-specific CD8 T cells shifted to an IFN--dominated
response (Fig. 4a).Whereas75%of the responding cells degranu-
lated upon stimulation,50% produced TNF-. The contribution
of IL-2-producing KK10-specific CD8 T cells dropped to 5%.
The KK10-specific CD8 T cells present during the chronic phase
of infection exhibited the same functional profile. This profile was
also shared with the HLA B27-restricted KK10 responses in two
Fig. 3. Comparison of 202-T07 KK10-specific CD8 T cell responses pre- and postinfection. (a) Expansion of KK10-specific CD8 T cells after HIV infection. CD8
expression is shown on the y axis; B27KK10 tetramer binding on the x axis. Values shown on the density plots depict the percentage of KK10-specific CD8 T cells. (b)
Vaccine-induced KK10-specific clonotypes are recalled after infection. The table depicts the TCRB variable family, CDR3 sequence, TCRB joining (TCRBJ) family, and
percentage frequency of each clonotype obtained from202-T07 [before infection (202-T07 vCP205), during the acute period (202-T07 acute), and through the chronic
infectionperiod(202-T07chronic)]andthetwochronicallyHIV-infectedcontrol subjects,2714Aand3963I.MatchingCDR3clonotypesequencesbetweendifferenttime
periods are highlighted in identical colors. (c) Vaccine-induced KK10-specific CD8 T cells shift to a predominant effectoreffectormemory phenotype after infection.
Red dotscontour overlays depict the B27 KK10 tetramer CD8 T cells. The bluegray density plot depicts total CD8 T cells.









HIV control subjects (Fig. 5a) despite differences in disease
courses between these subjects. 2714A is a nonprogressor who
displays a high-frequency (25%) B27KK10 tetramerCD8 T
cell response and is able to control viral load. 3963I is a progressor
and has required therapeutic intervention because of declining
CD4 counts. The only discernible functional difference between
these subjects was that, after in vitro stimulation (data not shown),
only 40% and 20% of the tetramerCD8 T cells were IFN-
CD107 in subjects 202-T07 and 3963I, respectively, compared
with 80% in 2714A. The percentage of responding B27KK10
tetramerCD8 cells in subject 202-T07 did not change between
the acute and chronic phase, despite an5-fold lower viral load at
the latter time point.
Although CD8 T cells that only degranulated or produced IL-2
dominated the vaccine-induced response toGag, IFN- production
dominated after infection similar to the profile exhibited against the
KK10 epitope (Fig. 4b). This functional profile remained consistent
into the chronic infection phase and was similar to the HIV
Gag-specific CD8 T cell response profile in 2714A (Fig. 5b).
The most dramatic functional shift observed in subject 202-T07
was in the CD4 T cell response to HIV Gag (Fig. 4c). Before
infection, this response was dominated by IL-2. After infection, the
response switched to a TNF--dominated response, with a near-
complete loss of IL-2 production. TheCD4Tcell response toHIV
Gag in 2714A was similarly dominated by TNF-, and IL-2 was
nearly absent; however, a large proportion of the responding CD4
T cells also produced IFN- (data not shown), similar to the chronic
Gag-specific CD4 T cell response in subject 202-T07 (Fig. 4c).
Early Viral Escape at the HLA B27 Restricted KK10 Epitope in Subject
202-T07. To determine whether the immunodominant KK10-
specific CD8 T cell response caused viral evolution, we sequenced
the Gag region containing this epitope from autologous plasma-
derived virus (Fig. 8) and integrated proviral DNA from PBMC
(data not shown).
In the acute infection period, there was no evidence of escape at
theKK10 epitope.However, by 32months after diagnosis,mutation
R264G at the anchor residue position 2 had occurred to diminish
peptide binding to HLA B27 (12). At this time, KK10-specific
CD8 T cells were still present, albeit with a substantially altered
clonal hierarchy (Fig. 3b). We determined that this mutation
occurred between the second and third year of infection (data not
shown). Escape at this epitope was not found in subject 2714A (19
of 19 clones sequenced; data not shown). Some sequence differ-
ences were noted in subject 3963I (KRWIIIGLHK, 23 of 23 clones
sequenced; data not shown) that do not affect the binding to
HLA-B27 (SYFPEITHI, www.syfpeithi.de).
Discussion
Development of an effective vaccine to suppress the worldwide
AIDS epidemic is amajor and pressing international goal. Here, we
have demonstrated that vaccine-induced T cell responses in an
HIV-1 vaccine recipient underwent functional and phenotypic
changes and failed to prevent infection and disease progression
after homosexual transmission. The vaccine-induced response was
composed of both helper and cytotoxic T cell components pre-
dicted to be necessary for vaccine-inducedprotection: killing ability,
cytokine production, proliferative capacity, polyclonality, and
memory phenotype (1). Moreover, the CD8 T cell response was
directed in part against a highly immunodominant and constrained
epitope correlated with long-term nonprogression and infrequent
and invariably late-stage viral escape (12–14). Therefore, we could
have expected a more favorable outcome after exposure to HIV-1.
The specific functional ability and phenotype required of vac-
cine-induced T cells to impart protection against HIV infection and
disease progression is unknown. In subject 202-T07, the vaccine-
induced T cells, in the presence of persistent antigenic stimulation,
rapidly acquired functional and phenotypic properties and impair-
ments characteristic of HIV-specific T cells in nonvaccinated
HIV-infected individuals. Moreover, as reported for other anti-
HIV CD8 responses (15, 16), the functional ability of the B27
KK10 tetramerCD8 T cells in 202-T07 was significantly com-
promised compared with patient 2714A, who controlled viremia
more effectively. This persistent impaired functionality of theCD8
T cell response in 202-T07 occurred despite the presence of an
HIV-specific CD4 response. Even more dramatic was the rapid
Fig. 4. Shift in T cell functional profile in 202-T07 after infection. The pie charts
(see Materials and Methods) depict the background-adjusted T cell functional
response to theKK10 epitope (CD8) (a), HIVGag (CD8) (b), andHIVGag (CD4) (c).
The value in the center of each pie chart represents the total response to the
respective stimuli. Left showsvaccine-induced responses,Center shows responses
during the acute phase, and Right shows chronic phase responses.
Fig. 5. HLA B27-restricted KK10 responses in HIV-infected controls. The pie
chartsdepict theCD8Tcell response toKK10 (a) in2714Aand3963IandHIVGag
(b) in 2714A. The value in the center of each pie chart represents the total
responsetotherespective stimuli. (c) Infection-inducedKK10-specificCD8Tcells
haveapredominant effectoreffectormemoryphenotype. Red contouroverlays
depict theB27KK10tetramerCD8Tcells,whereas thebluedensityplotdepicts
total CD8 T cells.
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loss of IL-2 production by the vaccine-induced Gag-specific CD4
T cells after infection as also observed in 2714A. The loss of IL-2
production after HIV infection could be a consequence of the
infection of antigen-specific CD4 T cells (17, 18), or due to
maturational changes in the CD4 T cell response. Whether the
phenotype and functional response pattern detected in this subject
is strictly related to the recombinant canarypox vector or will be
recapitulated in other vaccine strategies remains to be determined.
Additional analysis of clinical (but not immunological) data from
other subjects enrolled in recombinant HIV-1 canarypox vaccine
trials, who experienced breakthrough infection, suggest that vacci-
nation did not provide any tangible benefits against HIV infection
after exposure (19).
Although the frequency and breadth of the vaccine-induced T
cell response may have been suboptimal in subject 202-T07, they
were similar to those elicited by other candidate HIV vaccines
(20, 21) currently being tested in human trials. Importantly, data
collected from the simian immunodeficiency virus model (22,
23) and HIV infection (24, 25) suggest that these two parameters
are not likely determining factors in protection from infection
and progression.
An escapeKK10mutant epitope (R264G)with impaired binding
capacity to HLA-B27 was detected within 32 months of infection.
This escape, although rare, occurs on average nine years after
infectionk and is associated with disease progression in adults and
children (12–14). This observation could herald a potential danger
intrinsic to vaccine strategies that elicit T cell responses to HIV, as
previously suggested in refs. 12 and 26. Therefore, the role of virus
escape from vaccine-induced T cell responses versus the ability of
those T cell responses to control viral replication in the acute phase
will have to be carefully weighed.
As humoral immunity has been shown to correlate with
protection from a variety of acute viral illnesses in humans (27)
and in the simian immunodeficiency virus model (28, 29), the
lack of detectable vaccine-induced HIV-specific neutralizing
antibody responses could have likely contributed to the failure of
this vaccine to protect from infection. We also could not detect
noncytolytic CD8 suppressive reactivity in KK10-specific CD8
T cell lines derived from pre- or postinfection time points in
202-T07. The importance of this deficiency remains to be
determined in further vaccine trials (11, 30, 31).
At the first study point after infection, HIV-specific antibodies
were already present in subject 202-T07, and the subject immedi-
ately began antiretroviral therapy. Thus, we could not determine in
this individual whether the peak and set point of virus load were
affected by the vaccine-induced responses (26, 32–34). However,
time to undetectable virus load in 202-T07 was no different from
that observed in other individuals initiating antiretroviral therapy
during acute infection (35). Viral rebound to 3–6 104 copies per
ml after cessation of antiretroviral therapy and decline of absolute
CD4T cell counts to400 cells perl at subsequent visits suggest
that the vaccine-induced immune response did not contribute
substantially to control of virus replication or CD4 cell loss.
Overall rates of transmission per coital act among heterosexual
and homosexual groups do not appear to be significantly different
(36), suggesting that similar hurdles may exist for the prevention of
sexually acquired HIV in both groups. Subject 202-T07 could have
been exposed multiple times to HIV during the 4-month period of
high-risk behavior before infection. Once again, infection of subject
202-T07 may have been initially delayed but, ultimately, the vac-
cine-induced response was insufficient to prevent infection.
Although the data presented here are based on a single individ-
ual, the findings highlight the critical need to identify correlates of
protection and set parameters that can be used as a yardstick to
guide effective vaccine development. Until clear correlates are
established for protective immunity against HIV-1 infection, it is
likely that vaccine strategies that induce T cell responses in the
absence of effective antibody responses may be at risk of failing to
protect individuals, regardless of the specificity, functionality, fre-
quency, clonality, and breadth of those responses. Thus, even if a
vaccine is strongly immunogenic by all measured parameters, proof
of principle and phase III trials should be conducted that measure
both efficacy and possible immune correlates of protection.
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